Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 15/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26242811 | 0.82 | ALOX15 (0.37) | GSK3BALDH1A1MAPK1NPSR1LMNA | |
| SCHEMBL3057931 | 0.77 | PKM (0.37) | GSK3BALDH1A1MAPK1NPSR1LMNA | |
| SCHEMBL5104631 | 0.74 | PKM (0.52) | ALDH1A1MAPK1NPSR1LMNAMAPT | |
| SCHEMBL102004 | 0.74 | ALDH1A1 (0.40) | ALDH1A1MAPK1NPSR1LMNAMAPT | |
| SCHEMBL7965972 | 0.72 | IKBKB (0.42) | ALDH1A1NPSR1MAPTHPGDPKM | |
| SCHEMBL6788403 | 0.72 | GSK3B (0.70) | GSK3BALDH1A1MAPK1HIF1ANPSR1 | |
| SCHEMBL18719429 | 0.71 | POLB (0.38) | ALDH1A1MAPK1NPSR1LMNAMAPT | |
| SCHEMBL2028240 | 0.71 | ALOX15 (0.61) | GSK3BALDH1A1MAPK1NPSR1LMNA | |
| SCHEMBL2027674 | 0.69 | MAPT (0.47) | ALDH1A1MAPK1NPSR1LMNAMAPT | |
| SCHEMBL12195825 | 0.69 | NPC1 (0.47) | ALDH1A1LMNAMAPTHTTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3116858-B1 | AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC (JP) | 2020-11-11 | — | — | EP | disclosed |
| US-20180339993-A1 | AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2018-11-29 | — | — | US | disclosed |
| US-10093678-B2 | Azaspiro derivatives as TRPM8 antagonists | RAQUALIA PHARMA INC. (JP) | 2018-10-09 | — | — | US | disclosed |
| EP-3116858-A1 | AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS | RaQualia Pharma Inc. (JP) | 2017-01-18 | — | — | EP | disclosed |
| US-20170002016-A1 | AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2017-01-05 | — | — | US | disclosed |
| US-20170002016-A1 | AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2017-01-05 | — | — | US | disclosed |
| US-20170002016-A1 | AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2017-01-05 | — | — | US | disclosed |
| WO-2015136947-A1 | AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2015-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170002016-A1 | AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS | TRPM8, TRPM7, TRPM5 | GSK3B 2725/4885ALDH1A1 2024/4885MAPK1 976/4885 |
| US-10093678-B2 | Azaspiro derivatives as TRPM8 antagonists | TRPM8, TRPM7, TRPM5 | GSK3B 2725/4885ALDH1A1 2024/4885MAPK1 976/4885 |
| US-20180339993-A1 | AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS | TRPM8, TRPM7, TRPM6 | GSK3B 2584/4885ALDH1A1 2089/4885MAPK1 1050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.